Article
Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Transplantation proceedings - 1 May 2021
Pearston Aaron P, Ingemi Amanda I, Ripley Kathryn, Wilson Tyler J, Gruber Jacqueline, McMahon Megan, Sutton Sharon, Khardori Nancy
Abstract excerpt
Letermovir is an antiviral agent indicated for primary prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant recipients. In this case, UL97 mutation that conferred resistance to ganciclovir was seen in a patient 8 months after renal transplant. We report the off-label use of letermovir with adjunct hyperimmune CMV immunoglobulin in the successful...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
